To evaluate the efficacy of arterial infusion chemotherapy and embolization combined with iparplidutol-volerilis (QL1706) as first-line treatment for pancreatic cancer liver metastases based on progression-free survival (PFS).
1. Voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up visits.
Absolute neutrophil count (ANC) ≥1.5×10⁹/L (without G-CSF support within 14 days).
Platelets ≥100×10⁹/L (without transfusion within 14 days).
Hemoglobin >9 g/dL (without transfusion or erythropoietin use within 14 days).
**Subjects meeting any of the following criteria will be excluded from this study:**
Diagnosis of another malignancy within 5 years prior to the first dose, unless cured (exceptions include radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone radical resection).
Currently participating in an interventional clinical study or having received other investigational drugs or devices within 4 weeks prior to the first dose.
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2 agents, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137).